Luke Sergott
Stock Analyst at Barclays
(2.11)
# 2,655
Out of 4,792 analysts
248
Total ratings
36.65%
Success rate
-6.81%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Equal-Weight | $25 → $12 | $6.29 | +90.78% | 8 | Mar 4, 2025 | |
| SHC Sotera Health Company | Maintains: Overweight | $17 → $16 | $10.34 | +54.81% | 18 | Feb 28, 2025 | |
| CERT Certara | Maintains: Equal-Weight | $12 → $13 | $9.47 | +37.28% | 15 | Feb 28, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Overweight | $275 → $240 | $155.55 | +54.30% | 17 | Feb 21, 2025 | |
| EXAS Exact Sciences | Maintains: Overweight | $70 → $65 | $42.85 | +51.69% | 2 | Feb 20, 2025 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $166 → $160 | $137.92 | +16.01% | 4 | Feb 20, 2025 | |
| BRKR Bruker | Maintains: Overweight | $65 → $60 | $35.99 | +66.71% | 2 | Feb 14, 2025 | |
| TXG 10x Genomics | Maintains: Overweight | $18 → $15 | $7.59 | +97.76% | 10 | Feb 14, 2025 | |
| WAT Waters | Upgrades: Equal-Weight | $360 → $415 | $325.95 | +27.32% | 17 | Feb 10, 2025 | |
| A Agilent Technologies | Upgrades: Equal-Weight | $135 → $145 | $104.78 | +38.39% | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $130 → $100 | $73.27 | +36.48% | 16 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $23 | $15.10 | +52.37% | 22 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $96.04 | +45.77% | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $255 → $235 | $159.07 | +47.73% | 20 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $275 → $240 | $187.40 | +28.07% | 37 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $133.21 | +50.14% | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $40.67 | +47.53% | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $52 | $35.22 | +47.64% | 16 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $620 → $610 | $447.52 | +36.31% | 23 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $1.21 | +65.98% | 4 | May 10, 2024 |
Fortrea Holdings
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $25 → $12
Current: $6.29
Upside: +90.78%
Sotera Health Company
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $16
Current: $10.34
Upside: +54.81%
Certara
Feb 28, 2025
Maintains: Equal-Weight
Price Target: $12 → $13
Current: $9.47
Upside: +37.28%
ICON Public Limited Company
Feb 21, 2025
Maintains: Overweight
Price Target: $275 → $240
Current: $155.55
Upside: +54.30%
Exact Sciences
Feb 20, 2025
Maintains: Overweight
Price Target: $70 → $65
Current: $42.85
Upside: +51.69%
Charles River Laboratories International
Feb 20, 2025
Maintains: Equal-Weight
Price Target: $166 → $160
Current: $137.92
Upside: +16.01%
Bruker
Feb 14, 2025
Maintains: Overweight
Price Target: $65 → $60
Current: $35.99
Upside: +66.71%
10x Genomics
Feb 14, 2025
Maintains: Overweight
Price Target: $18 → $15
Current: $7.59
Upside: +97.76%
Waters
Feb 10, 2025
Upgrades: Equal-Weight
Price Target: $360 → $415
Current: $325.95
Upside: +27.32%
Agilent Technologies
Feb 10, 2025
Upgrades: Equal-Weight
Price Target: $135 → $145
Current: $104.78
Upside: +38.39%
Feb 10, 2025
Downgrades: Underweight
Price Target: $130 → $100
Current: $73.27
Upside: +36.48%
Feb 10, 2025
Maintains: Overweight
Price Target: $26 → $23
Current: $15.10
Upside: +52.37%
Feb 3, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $96.04
Upside: +45.77%
Feb 3, 2025
Maintains: Overweight
Price Target: $255 → $235
Current: $159.07
Upside: +47.73%
Jan 30, 2025
Maintains: Equal-Weight
Price Target: $275 → $240
Current: $187.40
Upside: +28.07%
Jan 23, 2025
Initiates: Overweight
Price Target: $200
Current: $133.21
Upside: +50.14%
Jan 23, 2025
Initiates: Overweight
Price Target: $60
Current: $40.67
Upside: +47.53%
Nov 19, 2024
Maintains: Overweight
Price Target: $55 → $52
Current: $35.22
Upside: +47.64%
Oct 23, 2024
Maintains: Equal-Weight
Price Target: $620 → $610
Current: $447.52
Upside: +36.31%
May 10, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $1.21
Upside: +65.98%